Dr. Weihsi Chen

Chemistry Division

Institute of Nuclear Energy Research, Tai Wan

Email: whchen@iner.gov.tw

Qualifications

1998 Ph.D., Chemistry Department, National Taiwan University, Taiwan, China

1990 M.D., Chemistry Department, National Taiwan University, Taiwan, China

Publications (Selected)

1. Chen WH, et al.: Determination of the metabolites of FEONM, an Alzheimer’s disease radio-imaging diagnosis agent in various biosystems using LC/Tandem Mass Spectrometry. (2017) EC Pharmacology and Toxicology 4.2: 40-50.
2. Chen WH, et al.: Liquid chromatography-mass spectrometry to monitor the labeling process stability and identify derivatives during the preparation of ¹⁸⁸Re-MN-16ET: A
3. radiopharmaceutical for hepatoma. (2017) Pharmaceutical Analytical Chemistry 3:1 DOI: 10.4172/2471-2698.1000121
4. Chen WH, et al.: Identification of impurities and forced degradation characterization of protected–H₃MN-16ET 16ET, a precursor for radiotherapy of hepatoma using liquid chromatography tandem mass spectrometry. (2016) International Journal of Chemical and Pharmaceutical Analysis V.3, I.2, Article ID: 877.
5. Chen WH, et al.: High performance liquid chromatography-tandem mass spectrometry method for ex vivo metabolic studies of a rhenium-labeled radiopharmaceutical for liver cancer. (2014) Eur. J. Mass Spectrom. 20, 375–382
6. Chen WH, et. al.: Forced degradation behavior of epidepride and development of a stability-indicating method based on liquid chromatography-mass spectrometry. (2014) J. Food and Drug Analysis 22, 248-256.